NKTRNektar Therapeutics
Price
-25%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growth fading, the market undecided.
Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. We apply our deep understanding of immunology to identify and create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development.
In the company’s own words · 10-K filed Mar 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Nektar Therapeutics (NKTR) reported revenue of $10M in Q2 2026 (quarter ended Jun 30, 2026), down 9.3% from the same quarter a year earlier. That came with net loss of $41M. For the full year FY2025, revenue was $55M (−44% year on year) and net income −$164M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was Non Cash Royalty Revenue Related To Sale Of Future Royalties at $11M, 97% of the disclosed total, well ahead of License Collaboration And Other at 2.5%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026.Regulation FD disclosure · press release
- Sep 25, 2026In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach of contract and breach of the implied covenant of good faith and fair dealing in …Other event · Form 8-K
- Aug 13, 2026Nektar Therapeutics Announces Second Quarter.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2025 · $11.8MThe company’s own SEC segment disclosure.
- Non Cash Royalty Revenue Related To Sale Of Future Royalties$11.5M97%
- License Collaboration And Other$300.0K3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.